Tuesday, August 27
- Experienced industry leader to head Complexa’s clinical development programs -
BERWYN, PA, August 19, 2019 – Complexa Inc. today announced the appointment of Theodore (Theo) Danoff, MD, PhD, as Chief Medical Officer. Dr. Danoff formerly served as Chief Medical Officer and Senior Vice President, Clinical and Medical Affairs for Clarus Therapeutics where he led strategy and oversight for all aspects of clinical development and medical affairs as well as regulatory affairs.
“Theo’s depth and breadth of experience in clinical development across a range of therapeutic areas will be extremely valuable to our company,” said Francisco Salva, President and Chief Executive Officer of Complexa. “We are fortunate to have his clinical leadership as we advance our lead drug candidate into late-stage clinical trials to treat debilitating fibrotic and inflammatory diseases in patients who currently have limited or no treatment options.”
In his role at Complexa, Dr. Danoff will lead the strategy, direction and execution of the company’s clinical development programs, including interactions with investigators, other clinical stakeholders and patient advocacy groups. He will also be a key medical representative of Complexa and its programs to external audiences in the medical and regulatory communities in addition to biopharmaceutical collaborators and partners.
During his tenure with Clarus Therapeutics, Dr. Danoff led the company’s clinical development efforts from Phase 1 to Phase 3 clinical trials, from strategy planning to study execution, NDA submissions, Advisory Committee presentations and FDA approval. Previously, he held senior level positions at Endo Pharmaceuticals where he supervised the overall clinical development of new products within the urology, endocrinology, pain and neuroscience therapeutic areas. While at Endo, he directed the launch of FORTESTA and oversaw the partnered development of BEMA-buprenorphine. He also led the clinical presentation at the Advisory Committee meeting for AVEED that resulted in its NDA approval. Dr. Danoff began his career in pharmaceuticals at GlaxoSmithKline where he held multiple roles of increasing responsibility that included leading translational medicine studies to support new and established therapeutic areas.
Dr. Danoff received both his medical degree and PhD in Immunology from the University of Chicago and his BS and MS degree in Chemistry from Emory University. He completed his nephrology fellowship and residency at the University of Pennsylvania. He has received numerous research awards and has published in a number of peer-reviewed journals. He holds board certifications in both internal medicine and nephrology.
Complexa Inc. is a patient-focused, science-driven, clinical stage biopharmaceutical company developing a novel class of compounds, nitrated fatty acids (NFAs), for the safe and effective treatment of debilitating fibrotic and inflammatory diseases. NFAs have demonstrated broad potential to be effective therapeutic agents in multiple disease indications in which oxidative stress, inflammation, fibrosis and/or direct tissue toxicity play significant roles. This class of molecules has the potential to be disease-modifying in many disorders, given the broad activity of NFAs. An experienced consortium of investors, including Andera Partners, HBM Healthcare Investments, JAFCO, New Enterprise Associates (NEA) and Pfizer Venture Investments have committed funding to advance a platform of NFA agents across multiple orphan disease indications. Complexa’s lead candidate, CXA-10, is currently in Phase 2 development for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). For more information, visit www.complexarx.com.
# # #
Sam Brown Inc.